Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics.

The nanoprecipitation method of nanosphere preparation offers several important advantages, such as readily adjustable and reproducible carrier size in the nanometer range and use of ingredients with low toxic potential, especially important for intravascular delivery. The applicability of the method to encapsulation of strongly lipophilic drugs has not been adequately addressed to date. In this study we applied nanoprecipitation to prepare PLA nanospheres loaded with a lipophilic tyrphostin compound, AG-1295, a potent antirestenotic agent. The effect of several formulation variables on the nanosphere basic properties (carrier size, drug release rate and drug recovery yield) was investigated. The nanosphere size was shown to be readily controlled by modifying the PLA and PLA non-solvent amounts in the organic phase. Carrier size and organic solvents' elimination rate are the main determinants of the drug release rate. The stability and drug recovery yield in the formulation depend on the drug to polymer ratio. Nanoprecipitation protocol modifications were suggested to produce nanospheres combining ultrasmall size (<100 nm) with high drug recovery yield, and to reduce the surfactant amount in the formulation.

[1]  Lisbeth Illum,et al.  Long circulating microparticulate drug carriers , 1995 .

[2]  J Molpeceres,et al.  Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. , 1996, Journal of pharmaceutical sciences.

[3]  R. Gurny,et al.  Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. , 2001, International journal of pharmaceutics.

[4]  I. Fishbein,et al.  Drug delivery systems for the treatment of restenosis. , 2000, Critical reviews in therapeutic drug carrier systems.

[5]  Michel Veillard,et al.  Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers , 1995 .

[6]  Y. Kawashima,et al.  In vitro drug release behavior of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. , 1994, Journal of pharmaceutical sciences.

[7]  M. R. Aberturas,et al.  Optimized preparation of poly d,l (lactic-glycolic) microspheres and nanoparticles for oral administration , 1996 .

[8]  J. Kreuter,et al.  Colloidal Drug Delivery Systems , 1994 .

[9]  J. Kreuter.  Nanoparticles and microparticles for drug and vaccine delivery. , 1996, Journal of anatomy.

[10]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[11]  T. Ehtezazi,et al.  Defining the drug incorporation properties of PLA-PEG nanoparticles. , 2000, International journal of pharmaceutics.

[12]  R. Müller,et al.  The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. , 1995, Advanced drug delivery reviews.

[13]  R. Gref,et al.  Lidocaine-loaded biodegradable nanospheres. I. Optimization Of the drug incorporation into the polymer matrix. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[14]  S. Benita,et al.  A new in vitro technique for the evaluation of drug release profile from colloidal carriers - ultrafiltration technique at low pressure , 1993 .

[15]  S. Davis,et al.  PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Y. I. Kim,et al.  Preparation and characterization of nanoparticles containing an antihypertensive agent. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  M. Alonso,et al.  Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. , 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  Ilia Fishbein,et al.  Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Robert Gurny,et al.  Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. , 2002, International journal of pharmaceutics.

[20]  Gilbert S. Banker,et al.  Pharmaceutical Dosage Forms: Disperse Systems , 1988 .

[21]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[22]  M. Hashida,et al.  Surface hydrophobicity of particles is not necessarily the most important determinant in their in vivo disposition after intravenous administration in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[23]  M. Alonso.  Nanoparticulate Drug Carrier Technology , 1996 .

[24]  Hatem Fessi,et al.  Nanocapsule formation by interfacial polymer deposition following solvent displacement , 1989 .

[25]  I. Fishbein,et al.  Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[26]  I. Fishbein,et al.  Formulation and Delivery Mode Affect Disposition and Activity of Tyrphostin-Loaded Nanoparticles in the Rat Carotid Model , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[27]  S. Benita,et al.  Sequential statistical optimization of a positively-charged submicron emulsion of miconazole. , 1996, Pharmaceutical development and technology.

[28]  Simon Benita,et al.  The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design , 1995 .

[29]  Y. Kawashima,et al.  Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  K. Avgoustakis,et al.  Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.

[31]  S. Davis,et al.  Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[32]  M C Davies,et al.  Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Yoshiaki,et al.  Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D, L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. , 1993 .

[34]  I. Fishbein,et al.  PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. , 1998, Circulation.

[35]  X Huang,et al.  On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Yoshiaki,et al.  Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. , 1999, International journal of pharmaceutics.